MarketFriction

Nureca Ltd

NSE NURECA · BSE 543264 · Medical Equipment & Supplies
₹349.85 -4.57%
NSE close2026-10-01
52 week range204.00 - 376.00
Market cap₹349 Cr.
P/E80.4
IPO 2021 · -13% since ESM Price band 5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales31.3522.3716.9720.2731.1926.4631.7434.1837.7439.6435.4140.34
Expenses29.9726.6221.4022.6333.5430.4730.5434.7434.4736.3941.1936.92
Operating Profit1.38-4.25-4.43-2.36-2.35-4.011.20-0.563.273.25-5.783.42
OPM %4.40%-19.00%-26.10%-11.64%-7.53%-15.15%3.78%-1.64%8.66%8.20%-16.32%8.48%
Other Income3.205.90-1.265.793.171.481.992.572.322.191.021.82
Interest0.080.110.180.150.270.180.620.250.460.280.300.20
Depreciation0.590.590.600.660.620.540.520.530.540.500.450.61
Profit before tax3.910.95-6.472.62-0.07-3.252.051.234.594.66-5.514.43
Tax %25.83%82.11%-35.86%36.64%585.71%-13.85%-20.00%34.15%21.13%19.96%10.71%30.93%
Net Profit2.890.17-4.151.66-0.48-2.802.470.813.633.73-6.093.07
EPS in Rs2.890.17-4.151.66-0.48-2.802.470.813.633.91-6.383.22
Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales629921325611192110147153
Expenses5390152200126102117147149
Operating Profit9106256-15-10-804
OPM %15%10%29%22%-13%-11%-7%0.1%2.7%
Other Income00387111287
Interest012100111
Depreciation000122222
Profit before tax996261-11-3158
Tax %30%26%26%26%-23%-30%37%58%
Net Profit664645-8-2124
EPS in Rs6,230.006,400.0046.3744.96-8.25-1.790.852.184.38
Dividend Payout %0%0%4%7%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%-7%10%24%
Compounded Profit Growth%-46%30%176%
Stock Price CAGR%-26%2%59%
Return on Equity%3%-1%1%
Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.010.01101010101010
Reserves815153193185183184171
Borrowings010443352
Other Liabilities15919128101113
Total Liabilities2434186219207205210196
Fixed Assets1141097914
CWIP00000000
Investments00033599411
Other Assets2333182175139104200182
Total Assets2434186219207205210196
Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity0-835110-3-193
Cash from Investing Activity-0-0-110-3-1618814
Cash from Financing Activity-0892-7-2-1-0-20
Net Cash Flow0-017-9-814-11-2
Free Cash Flow0-834-510-4-23-3
CFO/OP4%-82%81%35%-96%39%234%1,464%
Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days5247641461119
Inventory Days12393135174167186214187
Days Payable8933321324313520
Cash Conversion Cycle87107109165157161190186
Working Capital Days458561109156176163145
ROCE %57%67%33%-6%-4%1%3%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters63.24%63.24%63.24%63.24%63.78%64.06%64.30%64.33%64.97%64.97%68.09%68.09%
FIIs0.10%0.07%0.07%0.07%0.69%0.36%1.07%0.07%0.07%0.08%0.28%0.11%
DIIs0.00%0.00%0.00%0.00%0.00%0.04%0.04%0.04%0.04%0.04%0.24%0.24%
Public36.67%36.69%36.69%36.69%35.53%35.54%34.59%35.56%34.92%34.91%31.39%31.57%
No. of Shareholders52,25549,60045,99643,81341,98641,31439,30438,07537,46835,80134,55833,979

Fundamentals

Market Cap₹ 349 Cr.
Current Price₹ 362
Stock P/E80.4
Book Value₹ 189
ROCE3.30 %
ROE1.12 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)24%
Compounded Profit Growth (TTM)176%
Consolidated figures.
Valuation
Market capRs 350 Cr
Enterprise valueRs 307 Cr
P/E (TTM)80.61x
Price to book1.81x
Price to sales2.28x
EV / EBITDA26.68x
EV / EBIT32.63x
EV / sales2.01x
Earnings yield1.24%
P/E, 3-year average30.43x
P/B, 3-year average3.20x
P/E, 5-year average21.70x
P/B, 5-year average3.32x
Profitability
Operating margin (excl. other income)-11.10%
Operating margin (incl. other income)0.34%
EBITDA margin7.52%
Pre-tax margin5.34%
Net profit margin2.83%
Net margin, latest quarter7.61%
ROE-0.92%
ROCE-1.04%
ROA-0.87%
ROE, 3-year average6.49%
ROCE, 3-year average8.95%
ROA, 3-year average5.82%
ROE, 5-year average25.50%
ROCE, 5-year average30.05%
ROA, 5-year average16.40%
ROIC (approx.)4.41%
Tax rate29.53%
Other income / net worth5.44%
Growth
Sales growth (latest year)-17.42%
Sales CAGR, 3 years-24.48%
Sales CAGR, 5 years8.23%
Sales growth QoQ13.92%
Sales growth YoY (latest quarter)18.02%
Profit growth YoY (latest quarter)279.01%
Per share
EPS (TTM)Rs 4.34
EPS (latest year)Rs -1.79
EPS (latest quarter)Rs 3.07
EPS, 3-year averageRs 11.64
EPS, 5-year averageRs 1,296.26
Book value per shareRs 193.11
Sales per shareRs 153.13
Cash flow per shareRs -2.71
Free cash flow per shareRs -3.00
Dividend per share, 3-year averageRs 3.00
Dividend per share, 5-year averageRs 2.50
Dividends
Dividend payout, 3-year average6.67%
Dividend payout, 5-year average5.49%
Efficiency
Asset turnover0.45x
Fixed asset turnover12.93x
Inventory turnover2.02x
Inventory days181 days
Debtor days6 days
Debtors turnover56.75x
Creditor days20 days
Cash conversion cycle186 days
Working capital days145 days
Leverage
Total debtRs 3 Cr
Cash and bankRs 45 Cr
Net debtRs -43 Cr
Debt to equity0.01x
Net debt / EBITDA-3.72x
Interest coverage7.59x
Owners' fund to total sources94.13%
Debt to assets1.23%
Cash flow
Cash from Operating Activity (latest year)Rs -3 Cr
Cash from Investing Activity (latest year)Rs 18 Cr
Cash from Financing Activity (latest year)Rs -1 Cr
Net Cash Flow (latest year)Rs 14 Cr
Free cash flow (latest year)Rs -3 Cr
FCFE (approx.: FCF + change in debt)Rs -4 Cr
Cash from ops / profit, 5 years-0.21x
Statement figures
Net sales (TTM)Rs 153 Cr
Net sales (latest year)Rs 92 Cr
Sales (latest quarter)Rs 40 Cr
Operating profit excl. other income (latest year)Rs -10 Cr
Operating profit (latest quarter)Rs 3 Cr
Other income (TTM)Rs 7 Cr
EBITDA (TTM)Rs 12 Cr
PBDT (TTM)Rs 10 Cr
Profit before tax (TTM)Rs 8 Cr
Tax (latest year)Rs -1 Cr
Net profit (TTM)Rs 4 Cr
Net profit (latest year)Rs -2 Cr
Net profit (latest quarter)Rs 3 Cr
Depreciation (TTM)Rs 2 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 62 Cr
Total expenditure (latest year)Rs 102 Cr
Total income (latest year)Rs 102 Cr
Share capitalRs 10 Cr
ReservesRs 183 Cr
Shareholders' fundsRs 193 Cr
Total assetsRs 205 Cr
Net blockRs 7 Cr
Capital work in progressRs 0 Cr
InvestmentsRs 94 Cr
ReceivablesRs 2 Cr
InventoryRs 31 Cr
Other liabilitiesRs 10 Cr
Shares outstanding (crore)1.00
Ownership
Promoter holding68.09% (+3.76 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 80.6 is at the 58th percentile of its own 4.9-year range (median 70.5, low 5.5, high 335.1).
P/B 1.81 is at the 51th percentile (median 1.79).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodNURECANifty 50Difference
1 week+2.2%-2.8% +5.0 pts
1 month+3.2%-6.8% +10.0 pts
3 months+52.8%-7.6% +60.4 pts
6 months+69.2%+0.4% +68.8 pts
1 year+51.2%-9.9% +61.1 pts
2 years-8.0%-13.6% +5.5 pts
3 years+4.1%+14.2% -10.1 pts
5 years-78.4%+27.9% -106.3 pts

Red flags

F-score 4 of 8
explainWeak cash conversion Cash from operations was 26% of net profit over the last 3 years
lookRepeated losses Net loss in each of the last two years
lookRegulator order or action Regulator order or action 2026-08-21: Nureca Limited has informed the Exchange about Action(s) taken or orders passed
lookOn NSE surveillance On NSE surveillance: ESM
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹40 Cr +18.0% vs Jun 2025. Net profit ₹3 Cr +279.0%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Poly Medicure Ltd16,67152.112.5 %
Molbio Diagnostics Ltd14,47066.618.0 %
Fischer Medical Ventures Ltd2,35596.211.4 %
Tarsons Products Ltd1,7541484.59 %
Q-Line Biotech Ltd1,56927.822.5 %
Laxmi Dental Ltd1,05830.415.0 %
Hemant Surgical Industries Ltd86951.318.9 %
Vasa Denticity Ltd75462.37.54 %
OSEL Devices Ltd69123.624.4 %
Prevest Denpro Ltd46220.524.9 %
QMS Medical Allied Services Ltd41939.012.9 %
Aprameya Engineering Ltd20039.712.6 %
Avience Biomedicals Ltd19822.727.0 %
Earkart Limited17936.317.5 %
Vaidya Sane Ayurved Laboratories Ltd17619.615.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2025-12-12Buy Back
2024-07-11Annual General Meeting
2023-07-13Annual General Meeting
2022-09-01Annual General Meeting
2022-07-13Annual General Meeting
2022-02-24Interim Dividend - Rs 3 Per Share
2021-09-21 Annual General Meeting/Dividend - Rs 2 Per Share
DateTypeWhat it says
2026-10-01UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-09-30UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-09-29UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-09-28UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-09-26UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-09-25UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-09-10UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations).
2026-09-09UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations).
2026-08-29UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-08-21Regulatory actionAction(s) taken or orders passed
2026-08-11UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations )..
2026-08-07LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-07-28Shareholder meetingVoting results.
2026-07-28Shareholder meetingProceedings of Annual General Meeting held on July 28, 2026
2026-07-21UpdatesInvestor Presentation for Q1 & FY27.
2026-07-21Board meeting outcomeNureca Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-08UpdatesResubmission of a More Legible Copy of the Notice of 10th Annual General Meeting ( AGM ) and Annual Report 2025-26 submitted on 03 July 2026.
2026-07-07Disclosure under SEBI TakeovSaurabh Goyal has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made i...
2026-07-03Shareholder meetingNotice of Annual General Meeting to be held on July 28, 2026
2026-07-03UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-07-03UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-07-03UpdatesDisclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations ).
2026-07-01ResignationResignation of Director/KMP/SMP
2026-07-01ResignationResignation of Director/KMP/SMP
2026-07-01CessationCessation of Mr. Aryan Goyal as Whole time Director & CEO of the company w.e.f. close of business hours as on July 01, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
ESM: stage 1Scrip PE is greater than 50 (4 trailing quarters)
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03